Disease-Modifying Antirheumatic Drugs in Children With Juvenile Idiopathic Arthritis
Clinically Significant Outcomes of Interest (1 of 2)
Outcomes that were reported in the reviewed studies and analyzed in the CER include intermediate outcomes, such as disease activity and symptoms with assessment by physician global assessment of disease activity; by symptom response, for example, measured as the American College of Rheumatology Pediatric Improvement Score (e.g., 20%, 30%, or 50% from baseline); by parent/patient global assessments of well-being; and by active joint count. Laboratory measures of inflammation, such as erythrocyte sedimentation rate (ESR), and radiographic evidence of progression were other outcomes of interest.
Keywords: Juvenile idiopathic arthritis | JIA | JRA | juvenile rheumatic arthritis | JCA | juvenile chronic arthritis | DMARDs | disease-modifying | antirheumatic | anti-rheumatic | rheumatic | biologic | nonbiologic | non-biologic | physician global assessment | ACR Ped | parent global assessment | active joint count | erythrocyte sedimentation rate | ESR | radiographic
- Kemper A, Coeytaux R, Sanders G, et al. Disease-Modifying Antirheumatic Drugs (DMARDs) in Children With Juvenile Idiopathic Arthritis (JIA). Comparative Effectiveness Review No. 28 (Prepared by the Duke Evidence-based Practice Center under Contract No. HHSA 290-2007-10066-I). Rockville, MD: Agency for Healthcare Research and Quality; September 2011. AHRQ Publication No. 11-EHC039-EF. Available at www.effectivehealthcare.ahrq.gov/dmardsjia.cfm.
Your slide tray is being processed.